- Home
- PCSA vs ISPC Comparison
PCSA vs ISPC Comparison
Compare PCSA & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- ISPC
- Stock Information
- Founded
- PCSA 2011
- ISPC 2009
- Country
- PCSA United States
- ISPC United States
- Employees
- PCSA N/A
- ISPC N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- PCSA Health Care
- ISPC Health Care
- Exchange
- PCSA Nasdaq
- ISPC Nasdaq
- Market Cap
- PCSA 4.3M
- ISPC 4.7M
- IPO Year
- PCSA N/A
- ISPC 2021
- Fundamental
- Price
- PCSA $0.86
- ISPC $4.44
- Analyst Decision
- PCSA Buy
- ISPC
- Analyst Count
- PCSA 3
- ISPC 0
- Target Price
- PCSA $5.00
- ISPC N/A
- AVG Volume (30 Days)
- PCSA 26.8K
- ISPC 484.8K
- Earning Date
- PCSA 10-30-2024
- ISPC 11-07-2024
- Dividend Yield
- PCSA N/A
- ISPC N/A
- EPS Growth
- PCSA N/A
- ISPC N/A
- EPS
- PCSA N/A
- ISPC N/A
- Revenue
- PCSA N/A
- ISPC $10,390,702.00
- Revenue This Year
- PCSA N/A
- ISPC $13.82
- Revenue Next Year
- PCSA N/A
- ISPC $11.76
- P/E Ratio
- PCSA N/A
- ISPC N/A
- Revenue Growth
- PCSA N/A
- ISPC 0.74
- 52 Week Low
- PCSA $0.85
- ISPC $3.41
- 52 Week High
- PCSA $17.40
- ISPC $12.60
- Technical
- Relative Strength Index (RSI)
- PCSA 21.42
- ISPC 48.05
- Support Level
- PCSA $0.85
- ISPC $3.75
- Resistance Level
- PCSA $1.06
- ISPC $4.84
- Average True Range (ATR)
- PCSA 0.08
- ISPC 0.55
- MACD
- PCSA -0.02
- ISPC 0.01
- Stochastic Oscillator
- PCSA 2.89
- ISPC 49.82
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.